Refinement of immunohistologic parameters for Her2/neu scoring validation by FISH and CISH

被引:14
作者
Leong, Anthony S-Y
Formby, Mark
Haffajee, Zenobia
Clarke, Megan
Morey, Adrienne
机构
[1] Area Pathol Serv, HRMC, Immunohistol Unit, Div Anat Pathol, Newcastle, NSW 2310, Australia
[2] St Vincents Hosp, FISh Reference Lab, Sydney, NSW 2010, Australia
来源
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY | 2006年 / 14卷 / 04期
关键词
Her2/neu; immunohistochemistry; FISH; breast cancer;
D O I
10.1097/01.pai.0000210415.53493.d4
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
The conventional method of scoring Her2/neu immunostaining is recognized to result in a high false-positive rate among 2 + cases when compared with results obtained with fluorescence in situ hybridization (FISH); however, costs and convenience dictates that immunohistochemistry remains the screening test for Her2/neu status in patients with breast cancer. We describe refined criteria for scoring of Her2/neu on the basis of anatomic localization rather than the subjective assessment of intensity. The presence of a circumferential tram track pattern that results from the staining of apposing cell membranes in > 25% of the tumor cells was necessary for a 3 + score (Her2/ neu overexpressed) and the presence of the tram track pattern in < 25 % was scored 2 + (equivocal); granular and fragmented membrane staining was scored I + (negative). The tram track pattern of Her2/neu overexpression showed 100% concordance with gene amplification. FISH and CISH testing in selected cases from the other categories validated the revised scoring method. These criteria reduced the numbers of equivocal staining cases that required FISH testing.
引用
收藏
页码:384 / 389
页数:6
相关论文
共 24 条
[1]  
Acs G, 2003, APPL IMMUNOHISTO M M, V11, P222
[2]   Testing for erbB-2 by immunohistochemistry in breast cancer [J].
Allred, DC ;
Swanson, PE .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (02) :171-175
[3]   HER2 testing recommendations in Australia [J].
Bilous, M .
PATHOLOGY, 2001, 33 (04) :425-427
[4]  
CHECK W, 2005, CAP TODAY, V19, P37
[5]   THE SUBCELLULAR-LOCALIZATION OF THE NEU PROTEIN IN HUMAN NORMAL AND NEOPLASTIC-CELLS [J].
DEPOTTER, CR ;
QUATACKER, J ;
MAERTENS, G ;
VANDAELE, S ;
PAUWELS, C ;
VERHOFSTEDE, C ;
EECHAUTE, W ;
ROELS, H .
INTERNATIONAL JOURNAL OF CANCER, 1989, 44 (06) :969-974
[6]  
Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966
[7]  
HANNA W, 1990, MODERN PATHOL, V3, P455
[8]   Specificity of HercepTest in determining HER-2/neu status of breast cancers using the united states food and drug administration-approved scoring system [J].
Jacobs, TW ;
Gown, AM ;
Yaziji, H ;
Barnes, MJ ;
Schnitt, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :1983-1987
[9]   HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry - A study of interlaboratory agreement [J].
Jacobs, TW ;
Gown, AM ;
Yaziji, H ;
Barnes, MJ ;
Schnitt, SJ .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (02) :251-258
[10]  
Lehr HA, 2001, AM J CLIN PATHOL, V115, P814